Biomedical subjects

D P Rabussay

Publications and source records attributed to D P Rabussay.

4 recordsLinked to original sources

PubMed2002

Clinical evaluation of safety and human tolerance of electrical sensation induced by electric fields with non-invasive electrodes.

This paper reports the first clinical safety study of human tolerance of electrical sensation using non-invasive, flexible surface-type electrodes and exponentially decaying electric pulses. The study evaluated the effect of electric fields in the absence of a drug and an anesthetic, and was performed in light of potential applications in the field of erectile dysfunction (ED). Twenty impotent patients who had previously received injection or intraurethral therapies were enrolled in the study. Voltage escalations from 50 to 80 V (in 10-V increments) with a single pulse of 3-ms duration were performed with meander-type electrodes placed on the shaft and part of the glans of the penis. The electric fields-induced sensation was assessed via a pain scale from 0 to 10. All 20 patients, who were free to withdraw from the study at any point, completed the voltage escalation study. No clinical safety concerns were apparent and no skin irritation was observed after electric treatment. Our initial study indicates that the pulses in the tested voltage range were well tolerated by most patients. In previous animal experiments under analogous experimental conditions, the application of 50 V has been found effective for transdermal drug delivery into the penis.

Adaptation, Physiological↗

PubMed1997

Improving glove barrier effectiveness.

Perioperative staff members depend on surgical gloves to prevent disease transmission between themselves and patients, but these gloves frequently fail during use. Three approaches can make surgical gloves more effective barriers: preventing glove failures, monitoring glove integrity, and improving glove quality. Failure prevention includes modifying surgical techniques, improving instruments and equipment, streamlining teamwork, selecting the most appropriate gloves, double gloving, and performing preventive glove changes. Glove integrity monitoring can be performed visually or by feel, by wearing glove pairs with color-puncture indicators, or by using electronic monitoring devices. Glove quality improvements must be accompanied by testing methods that reflect in-use conditions. A glove rating system that is based on in-use performance may enhance glove safety substantially.

Equipment Failure↗

PubMed1997

Surgical glove failures in clinical practice settings.

Health care personnel often pay little attention to the barrier effectiveness of the surgical gloves they use in clinical settings. They may assume that all surgical gloves provide adequate protection against the transfer of bloodborne pathogens, chemicals, or mutagenic substances. Perioperative staff members frequently are unaware that their surgical gloves have failed until they find blood on their hands after operative procedures are completed. In this first article of a three-part series, the authors review current surgical glove testing standards, define surgical glove failure, and describe the reasons that surgical glove failure occurs in clinical practice settings.

Equipment Failure↗

PubMed1983

Initiation of transcription at phage T4 late promoters with purified RNA polymerase.

We have previously identified T4 late promoters governing the in vivo expression of T4 late genes 23 and 24 (P23 and P24). T4 late transcription in vivo is known to involve the binding of at least five phage-coded proteins to the bacterial RNA polymerase and normally requires concurrent DNA replication for DNA template activation. We show here that in vitro transcription, primarily of plasmids carrying T4 genes 23 and 24, by RNA polymerase purified from Escherichia coli at late times after T4 infection allows specific initiation at P23 and P24 in the absence of DNA replication. These promoters are not utilized by E. coli RNA polymerase holoenzyme, by RNA polymerase core, or by T4-modified RNA polymerase purified from cells infected with a T4 gene 55 mutant (gene 55 codes for an RNA polymerase binding protein required for late transcription). The utilization of P23 and P24 in vitro is sharply inhibited by NaCl concentrations greater than 100 mM, and this inhibition is partly reversed by the addition of 10% DMSO. Relaxation of plasmid DNA containing P23 (with topoisomerase I) reduces P23 utilization at low salt (50 mM Na+) and nearly abolishes it at high salt (250 mM Na+). P23 utilization is discernible in linear, glucosylated hydroxymethylcytosine-containing T4 virion DNA.

Cell-Free System↗